

References

S-250

1. O'Brart DPS, Kwong TQ, Patel P, *et al.* Long-term follow-up of riboflavin/ultraviolet A (370 nm) corneal collagen cross-linking to halt the progression of keratoconus. *Br J Ophthalmol.* 2013;97:433-437.
2. Li J, Ji P, Lin X. Efficacy of corneal collagen cross-linking for treatment of keratoconus: a meta-analysis of randomized controlled trials. *Plos One* [serial online]. 2015;10(5):e0127079. Accessed September 21, 2017.
3. Wittig-Silva C, Chan E, Islam FM, Wu T, Whiting M, Snibson GR. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology.* 2014;121(4):812-21.
4. National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013; <https://www.nice.org.uk/guidance/ipg466>. Accessed September 21, 2017.
5. Devogelaer JP, Boutsen Y, Gruson D, Manicourt D. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment? *Rheum Dis Clin North Am.* 2011;37(3):365-386.
6. Laster AJ, Tanner SB. Duration of treatment in postmenopausal osteoporosis: How long to treat and what are the consequences of cessation of treatment? *Rheum Dis Clin North Am.* 2011;37(3):323-336.
7. Bell KJ, Haven A, Irwig L, *et al.* The potential value of monitoring bone turnover markers among women on alendronate. *J Bone Miner Res.* 2011 Sep 28. doi: 10.1002/jbmr.525. [Epub ahead of print].
8. Vasikaran S, Eastell R, Bruyère, *et al.* Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards. *Osteoporosis Int.* 2011;22:391-420.
9. Vasikaran S, Cooper C, Eastell R, *et al.* International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. *Clin Chem Lab Med.* 2011;49(8):1271-1274.